Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01046357 · ClinicalTrials.gov registry record · Phase 1

A Study in Healthy Volunteers to Assess the Tolerability and Blood Levels of a Single Dose of AZD7687

A Phase 1 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
64
Enrollment target

NCT01046357 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 64 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01046357, a Phase 1 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
64 participants
Enrollment target

Study Summary

This is a Phase I, first time in human, randomised, blinded, placebo-controlled, single ascending dose study in healthy male volunteers conducted at a single centre. The effect of food on the pharmacokinetics of AZD7687 will also be studied. The study will consist of two parts, a dose escalation part and a food interaction part. The two parts will be run in parallel. In total, 64 healthy volunteers divided in 8 different panels (8 volunteers per cohort) will be exposed to single doses during the dose escalation. Each subject will receive dose only once, except for the volunteers included in the dose steps repeated for food interaction.

Interventions

  • DRUG Placebo
  • DRUG AZD7687

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2009-11
Est. Completion 2010-06
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT01046357

The ClinicalTrials.gov registry entry for NCT01046357 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01046357 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01046357 about?

NCT01046357 is a clinical study titled "A Study in Healthy Volunteers to Assess the Tolerability and Blood Levels of a Single Dose of AZD7687". This is a Phase I, first time in human, randomised, blinded, placebo-controlled, single ascending dose study in healthy male volunteers conducted at a single centre. The effect of food on the pharmacokinetics of AZD7687 will also be studied. The study will consist of two parts, a dose escalation pa...

What is the current status of trial NCT01046357?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2009-11. Estimated completion is 2010-06.

What interventions are being tested in trial NCT01046357?

The interventions under investigation include: Placebo (DRUG), AZD7687 (DRUG).

Who is sponsoring clinical trial NCT01046357?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.